| Name | Biodexa Pharmaceuticals |
|---|---|
| Epic | BDRX |
| Isin | GB00BNGF1L75 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 3.75p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £3.55 | Debt ratio | n/a |
| Shares in issue | 88.35 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -62.38 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -140 | 52-week high / low | 3.75p / 270.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Biodexa Pharmaceuticals |
|---|---|
| Address | 1 Caspian Point, Caspian Way, Cardiff, United Kingdom, CF10 4DQ |
| Telephone | |
| Website | http://www.midatechpharma.com/ |
| Director | Position |
|---|---|
| Mr Stephen Stamp | CEO |
| Dr Stephen Parker | Non-Executive Chairman |
| Mr Simon Turton | Senior Independent Non-Executive Director |
| Mr Simon de Vries | Independent Non-Executive Director |
| Assets £ (m) | 2021 | 2020 | 2019 |
|---|---|---|---|
| Reporting date | 31/12/21 | 31/12/20 | 31/12/19 |
| Intangible asssets and goodwill | n/a | n/a | 12.38 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 1.15 | 0.54 | 17.16 |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 1.03 | 0.57 | 0.99 |
| Cash and equivalents | 10.06 | 7.55 | 10.93 |
| Other current assets and asset held for resale | 0.67 | 1.16 | 1.82 |
| Total of all assets | 12.91 | 9.82 | 30.89 |
| Liabilities £ (m) | 2021 | 2020 | 2019 |
|---|---|---|---|
| Short term liabilities | 1.84 | 2.99 | 5.67 |
| Long term liabilities | 0.62 | 0.11 | 5.67 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 2.46 | 3.1 | 11.34 |
| Net assets £ (m) | 2021 | 2020 | 2019 |
|---|---|---|---|
| Net assets | 10.45 | 6.72 | 19.56 |
| Equity £ (m) | 2021 | 2020 | 2019 |
|---|---|---|---|
| Share capital | 1.1 | 1.06 | 1.02 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -127.8 | -122.43 | -99.84 |
| Share premium account | 83.43 | 74.36 | 65.88 |
| Total equity | 10.45 | 6.72 | 19.56 |
| Income £ (m) | 2021 | 2020 | 2019 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -7 | -23.04 | -11.32 |
| Pre-tax profit | -6.11 | -23.47 | -10.92 |